Venous Leg Ulcer
Conditions
Brief summary
The primary objective of the study is to demonstrate that the HM242-Gel performs at least comparably to INTRASITE Gel with regard to wound healing.
Interventions
DEVICEHM242-Gel
HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
DEVICEIntrasite Gel
HM242-Gel compared to Intrasite Gel in patients with a venous leg ulcer
Sponsors
B. Braun Ltd. Centre of Excellence Infection Control
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males or females of at least 18 years at the time of enrolment 2. The legal capacity and ability to understand the nature, risks, significance and scope of the clinical trial and to determine his or her will accordingly 3. Signed form of consent, including the understanding of and willingness by the patient to participate in the clinical study and ability to comply with study procedures and study visit schedule 4. Patients must be willing to have all dressing changes performed by the wound specialist, with no treatments at home 5. Presence of at least one venous ulcer of the lower leg extending through the full thickness of the skin but not down to muscle, tendon or bone 6. Size of study ulcer ≥ 2cm² and ≤ 100cm² measured using the tracing method. 7. Presence of venous leg ulcer for at least 6 weeks, but not longer than 12 months 8. Ankle Brachial Pressure Index (ABI) \> 0.75 9. In the case of a female patient of childbearing potential, willingness to use highly effective methods of contraception (failure rate of \< 1% when used consistently and correctly);acceptable contraceptive measures in this trial are: combined pill and progestin-only pill, contraceptive patch, ring or injection, Etonogestrel implant, intrauterine device (IUD) (copper and Levonogestrel), male sterilization (vasectomy), female sterilization (abdominal, laparoscopic, hysteroscopic), or sexual abstinence.
Exclusion criteria
1. Patients kept in an institution due to an official or court order 2. Patients dependent on the Sponsor, Investigator or Site 3. Patients suspected of having SARS-CoV-2 infection or COVID-19 disease 4. Study ulcer judged by the Investigator to be caused by a medical condition other than venous insufficiency 5. Study ulcer with signs and symptoms of infection, or under suspicion of cancer 6. Study ulcer under treatment with topical antimicrobials within past two weeks or systemic antimicrobial treatment within past two weeks 7. In the case of heavily exuding ulcers, if in the opinion of Investigator the patient is not suitable for treatment with gel 8. More than two venous leg ulcers or more than two chronic wounds 9. Dementia stage greater than 3 according to Reisberg 10. Known allergies against wound dressings used in the study 11. Known chronical skin diseases, dermatoses, or known allergies or other conditions which might trigger dermatitis 12. Acute cases of substance use disorders (ICD-10 F1x.1 or F1x.2) 13. Buerger's disease 14. Participation in Medical Device trials less than 4 weeks ago or participation in Drug trials less than six months ago 15. Terminally ill patients 16. Patients with poorly managed diabetes mellitus: absence of a glycated hemoglobin test within the last 3 months or a result of HbA1c ≥ 8% not older than 3 months, or a major diabetes-related incident within the past 4 weeks 17. Ulcers of diabetic origin 18. Patients under treatment with systemic corticosteroids, immunosuppressant, cytotoxic chemotherapy, or radiotherapy 19. Presence of one or more medical conditions (other than venous insufficiency and diabetes) as determined by medical history, which: * Is known to interfere with the wound healing process (e.g. arteriopathy, vasculitis, rheumatoid arthritis, systemic lupus erythematosus, other auto-immune diseases, cancer, immunodeficiency, severe lymphedema of the leg, thrombophilia) * In the opinion of the Investigator, would make the patient an inappropriate candidate for this venous ulcer healing study (e.g. malnutrition, hygiene, obesity) 20. Pregnant or lactating patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The primary objective of the study is to demonstrate that the HM242-Gel performs at least comparably to INTRASITE Gel with regard to wound healing. | 28 days | The primary variable is defined as the relative reduction of the wound area of a patient in percentage 28 days (4 weeks) after baseline. The wound size area is measured on site by the tracing method. |
Countries
Czechia, Slovakia
Outcome results
None listed